This paper reports a rapid HILIC-ESI–MS assay to quantify dipalmitoylphosphatidylcholine
(DPPC) as component of lung surfactant for nanosafety studies. The technique was used to …

Understanding the interaction between pulmonary surfactant (PS) and inhalable pollutants
is vital for risk assessment of respiratory health. Here, PS extracted from porcine lung (EPS) …

Cultured human lung epithelial cells, particularly A549 cells, are commonly used as the in
vitro model to evaluate the inhalational toxicity of nanoparticles (NPs). However, A549 cells …

Rationale Inhaled nanoparticles may cause adverse effects due to inactivation of lung
surfactants. We have studied how three different nanoparticles interact with dipalmitoyl …

Because of an increasing exposure to environmental and occupational nanoparticles (NPs),
the potential risk of these materials for human health should be better assessed. Since one …

The air–blood barrier is a very thin membrane of about 2.2 µm thickness and therefore
represents an ideal portal of entry for nanoparticles to be used therapeutically in a …

Lung lining fluid is the first biological barrier nanoparticles (NPs) encounter during
inhalation. As previous inhalation studies revealed considerable differences between …

A systematic investigation of interaction of multi-carbon nanoparticles, obtained from soot,
with dipalmitoyl phosphatidylcholine (DPPC), a clinical pulmonary phospholipid surfactant …

Understanding the interaction between inhaled nanoparticles and pulmonary surfactant is a
prerequisite for predicting the fate of inhaled nanoparticles. Here, we introduce a quartz …

Various cell types are compromised by synthetic amorphous silica (SAS) if they are exposed
to SAS under protein-free conditions in vitro. Addition of serum protein can mitigate most …